MedXY
Not signed in Sign in / Register
Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

RAAS-modifying drugs

  • Home
  • RAAS-modifying drugs
Balancing Accuracy and Practicality: Should RAAS-Modifying Drugs Be Withdrawn in Primary Aldosteronism Diagnosis?
Posted inDiabetes & Endocrinology Nephrology news

Balancing Accuracy and Practicality: Should RAAS-Modifying Drugs Be Withdrawn in Primary Aldosteronism Diagnosis?

Posted by By MedXY 09/15/2026
This article examines the debate on whether RAAS-modifying antihypertensives should be stopped before testing for primary aldosteronism, weighing diagnostic accuracy against patient safety and feasibility.
Read More
  • Stratifying Risk for Further Retinal Intervention After Laser Retinopexy: The Impact of Cumulative Clinical Factors
  • Visual Performance of a Refractive Extended Depth of Field Intraocular Lens in Monovision and Emmetropic Settings: A Comprehensive Review
  • Intraoperative Botulinum Toxin Injection to Reduce Postoperative Sialocele After Parotidectomy: A Retrospective Cohort Analysis
  • Outcomes of Laryngeal Carcinoma Treatment in Female Patients: A Multicenter Retrospective Analysis
  • Imaging-Guided Classification and Diagnostic Pathways for Appendiceal Abscesses: Practical Takeaways from the 2025 Italian Consensus
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号
  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology GLP-1 receptor agonists heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation MASLD mental health Mortality multiple myeloma myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prognosis public health quality of life randomized clinical trial randomized controlled trial risk stratification semaglutide SGLT2 inhibitors stroke type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top